Venus Remedies reported a consolidated net profit of ₹22.97 crore for the quarter ended June 30, 2026, representing a 118% increase from ₹9.60 crore in the corresponding period of the previous year. Revenue from operations grew to ₹178.86 crore from ₹137.18 crore in Q1FY25. The company's board approved the unaudited financial results for the quarter during a meeting held on July 20, 2026.

The standalone financial results showed a net profit of ₹25.53 crore, compared to ₹11.70 crore in the same quarter last year. Standalone revenue from operations was reported at ₹178.80 crore. The results were reviewed by the Audit Committee and the statutory auditors, J. K. Jain & Associates, provided a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company's earnings per share (EPS) on a consolidated basis for the quarter was ₹17.18, up from ₹7.18 in the previous year. EBITDA for the quarter stood at ₹36.81 crore compared to ₹18.80 crore in Q1FY25, with the EBITDA margin expanding to 19.10% from 7.66% in the year-ago period. Total comprehensive income for the period stood at ₹28.88 crore. The board noted that the group has only one reportable segment, Pharmaceuticals.

The following table summarises the key consolidated financial metrics for the quarter:

Corporate Governance Updates

The board approved revisions to the proposed alteration of the Memorandum of Association (MOA). These changes are intended to align the Object Clause with the provisions of the Companies Act, 2013 and update the main objects to reflect current business practices. The principal business activities remain unchanged, and the company continues to operate in the pharmaceutical sector. The revised MOA will be placed before shareholders for approval via a Special Resolution at the ensuing 37th Annual General Meeting.

Subsidiary and Auditor Observations

The independent auditor's report highlighted an emphasis of matter regarding outstanding share application money amounting to ₹2,859.72 lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary. The share allotment is pending as it is not mandatory under German laws. Management stated the investment is strategic and intends to recover the amount following the restructuring of European operations in FY 2026-27. The auditor also noted that Venus Pharma GmbH reported a net loss of ₹2.55 crore for the quarter, while its step-down subsidiary, Venus Pharma Kft, reported nil revenue and profit.

Venus Remedies Limited has recommended a final dividend of ₹10 per equity share, equivalent to 100% of the face value, for the financial year ended March 31, 2026. The dividend will be paid to shareholders whose names appear in the Register of Members or the list of beneficial owners provided by depositories as of the close of business hours on Friday, August 7, 2026, which has been fixed as the record date. The company stated that the dividend will be disbursed within 30 days from the date of the ensuing Annual General Meeting.

The Board of Directors has scheduled the 37th Annual General Meeting (AGM) for Thursday, August 20, 2026, at 11:30 pm IST. The meeting will be conducted via video conferencing to transact the business set forth in the notice. Members will have the opportunity to cast their votes on the resolutions through an e-voting system, with detailed procedures to be outlined in the AGM notice.

In compliance with regulatory circulars, the notice of the AGM and the Annual Report for FY 2025-26 will be sent via email to members whose email addresses are registered with the company, its Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited, or the depositories. Physical letters containing the web-link to access these documents will be sent to members who have not registered their email addresses.

The company has advised members to validate and update their bank account details and other KYC information to ensure the direct credit of dividends. Members holding shares in physical form must submit requisite forms to the RTA, while those holding shares in dematerialized form must update their details with their respective depository participants. The company emphasized that dividends will be paid only through electronic mode upon the updation of KYC and bank account details.

Venus Remedies Limited also noted that tax will be deducted at source (TDS) on the dividend payment in accordance with the Income Tax Act, 2025. The applicable tax rate will depend on the residential status of the members and the documents submitted. A detailed note regarding the tax rates and required documentation will be included in the notes to the AGM notice.